{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:53:26Z","timestamp":1790844806847,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A subset of individuals with episodic migraine (EM) and chronic migraine (CM) does not respond to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), even after switching agents. Although atogepant is effective in EM and CM, its role in individuals unresponsive to anti-CGRP mAbs remains to be elucidated. We hypothesize that atogepant may be a viable preventive option in these cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study in EM and CM individuals who discontinued anti-CGRP mAbs due to lack or loss of efficacy and were subsequently treated with atogepant. The primary endpoint was the \u226550% response rate in monthly headache days (MHDs). Secondary outcomes included \u226530% and \u226575% response rates in MHDs, response rates in monthly moderate-to-severe headache days (MSHDs), and changes in MHDs, MSHDs, acute medication days (AMDs) and Headache Impact Test (HIT-6). Patient Global Impression (PGI) scores and adverse events (AEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 213 screened records, 44 participants met inclusion criteria; 39 (88.6%) were female and 39 (88.6%) had CM. Prior use of anti-CGRP mAbs included erenumab in 11.4% of participants, galcanezumab in 52.3% and fremanezumab in 86.3%. After three months, 18.2% achieved a \u226550% reduction in MHDs; \u226530% and \u226575% response rates were 25.0% and 6.8% respectively. For MSHDs, \u226530%, \u226550% and \u226575% response rates were 47.6%, 33.3% and 19.0%, respectively. Median MHDs decreased from 24.5 (interquartile range (IQR) =\u200916.0\u201330.0; range 9.0\u201331.0) to 21.5 (IQR\u2009=\u200910.0\u201330.0; range 3.0\u201331.0;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.011), and median MSHDs from 15.0 (IQR\u2009=\u200910.0\u201325.5; range 5.0\u201330.0) to 12.0 (IQR\u2009=\u20095.9\u201319.0; range 0.0\u201330.0;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001). AMDs and HIT-6 scores also showed significant reductions. According to the PGI scale, 59.1% of individuals reported some degree of improvement. AEs occurred in 50.0% of participants, most commonly constipation (31.8%). Five (11.4%) participants discontinued treatment due to side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>After three months of treatment, atogepant led to a clinically meaningful improvement in a subset of participants. It may be a valuable preventive option for individuals unresponsive to anti-CGRP mAbs and warrants further investigation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251346925","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:09:13Z","timestamp":1749697753000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-9484","authenticated-orcid":false,"given":"Alex","family":"Jaimes","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"},{"name":"School of Medicine, Autonomous University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Rodr\u00edguez-Vico","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pajares","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Eguilior Caffarena","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lena","family":"Nystrom Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-682X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Porta-Etessam","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241273968"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15816"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01498-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2025.2461766"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14865"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211048765"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01394-0"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1154420"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231160519"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002946"},{"key":"e_1_3_2_12_2","first-page":"87","article-title":"Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?","volume":"75","author":"L\u00f3pez-Moreno Y","year":"2022","unstructured":"L\u00f3pez-Moreno Y, Castro-S\u00e1nchez MV, Garc\u00eda-Trujillo L, et al. Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one? Rev Neurol 2022; 75: 87\u201391.","journal-title":"Rev Neurol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00025-5"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210212"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209584"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01698-8"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"e_1_3_2_22_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rev. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251335927"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04250-3"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01183-6"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2211-17.2017"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0576-17.2017"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221083544"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae062"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01736-z"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201568"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251346925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251346925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251346925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:55Z","timestamp":1777387615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251346925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/03331024251346925"],"URL":"https:\/\/doi.org\/10.1177\/03331024251346925","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"03331024251346925"}}